Tumor-infiltrating γδ T lymphocytes: Pathogenic role, clinical significance, and differential programing in the tumor microenvironment

Frontiers in Immunology

Volumn 5, Issue NOV, 2014, Pages

  Lo Presti, Elena ^a   Dieli, Franceso ^a   Meraviglia, Serena ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Il 17; Immunosuppression; Til; Tumor microenvironment; T cells

Indexed keywords

ADENOSINE DERIVATIVE; CHEMOKINE RECEPTOR CXCR2; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GERANYLTRANSFERASE; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ZOLEDRONIC ACID;

ANTIGEN RECOGNITION; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER PROGNOSIS; CD3+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; GAMMA DELTA T LYMPHOCYTE; HEAT SHOCK; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; MEMORY T LYMPHOCYTE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OSTEOPOROSIS; OXIDATIVE STRESS; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; STROMA; SUPPRESSOR CELL; SURVIVAL; T LYMPHOCYTE ACTIVATION; TARGET CELL; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84919395329     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00607     Document Type: Review

References (81)

1. Hayday AC. γδ T cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol (2000) 18:975-1026. doi: 10.1146/annurev.immunol.18.1.975
2. Bonneville M, O'Brien RL, Born WK. γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol (2010) 10:467-78. doi:10.1038/nri2781
3. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science (1998) 279:1737-40. doi:10.1126/science.279.5357.1737
4. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, et al. Vδ1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res (2004) 64:9172-9. doi:10.1158/0008-5472.CAN-04-2417
5. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature (1995) 75:155-8. doi:10.1038/375155a0
6. Eberl M, Hintz M, Reichenberg A, Kollas AK, Wiesner J, Jomaa H. Microbial isoprenoid biosynthesis and human γδ T cell activation. FEBS Lett (2003) 544:4-10. doi:10.1016/S0014-5793(03)00483-6
7. Sireci G, Espinosa E, Di Sano C, Dieli F, Fournié JJ, Salerno A. Differential activation of human γδ cells by nonpeptide phosphoantigens. Eur J Immunol (2001) 31:1628-35. doi:10.1002/1521-4141(200105)31:5<1628::AID-IMMU1628>3.0.CO;2-T
8. Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol (2013) 13:88-100. doi:10.1038/nri3384
9. Scotet E, Martinez LO, Grant E, Barbaras R, Jeno P, Guiraud M, et al. Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity (2005) 22:71-80. doi:10.1016/j.immuni.2004.11.012
10. Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, El Daker S, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat Immunol (2013) 14:908-16. doi:10.1038/ni.2665
11. Harly C, Guillaume Y, Nedellec S, Peigné CM, Mönkkönen H, Mönkkönen J, et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood (2012) 120:2269-79. doi:10.1182/blood-2012-05-430470
12. Sandstrom A, Peigné CM, Léger A, Crooks JE, Konczak F, Gesnel MC, et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity (2014) 40:490-500. doi:10.1016/j.immuni.2014.03.003
13. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K. Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol (2009) 144:245-50. doi:10.1111/j.1365-2141.2008.07435.x
14. Li J, Herold MJ, Kimmel B, Muller I, Rincon-Orozco B, Kunzmann V, et al. Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vγ9Vδ2 T cells. J Immunol (2009) 182:8118-24. doi:10.4049/jimmunol.0900101
15. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor γδ T cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med (2003) 197:163-8. doi:10.1084/jem.20021500
16. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C, et al. Differentiation of effector/memory Vδ2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med (2003) 198:391-7. doi:10.1084/jem.20030235
17. Caccamo N, Meraviglia S, Ferlazzo V, Angelini D, Borsellino G, Poccia F, et al. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vγ9Vδ2 naive, memory and effector T cell subsets. Eur J Immunol (2005) 35:1764-72. doi:10.1002/eji.200525983
18. Caccamo N, Todaro M, Sireci G, Meraviglia S, Stassi G, Dieli F. Mechanisms underlying lineage commitment and plasticity of human γδ T cells. Cell Mol Immunol (2013) 10:30-4. doi:10.1038/cmi.2012.42
19. Sireci G, Champagne E, Fournié JJ, Dieli F, Salerno A. Patterns of phosphoantigen stimulation of human Vγ9Vδ2 T cell clones include Th0 cytokines. Hum Immunol (1997) 58:70-82. doi:10.1016/S0198-8859(97)00211-5
20. Wesch D, Glatzel A, Kabelitz D. Differentiation of resting human peripheral blood γδ T cells toward Th1- or Th2-phenotype. Cell Immunol (2001) 212:110-7.
21. Ness-Schwickerath KJ, Jin C, Morita CT. Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vγ9Vδ2 T cells. J Immunol (2010) 184:7268-80. doi:10.4049/jimmunol.1000600
22. Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, Stassi G, et al. Differentiation, phenotype and function of interleukin-17-producing human Vγ9Vδ2 T cells. Blood (2011) 118:129-38. doi:10.1182/blood-2011-01-331298
23. Fenoglio D, Poggi A, Catellani S, Battaglia F, Ferrera A, Setti M, et al. Vδ1 T lymphocytes producing IFN-γ and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans. Blood (2009) 113:6611-8. doi:10.1182/blood-2009-01-198028
24. Bansal RR, Mackay CR, Moser B, Eberl M. IL-21 enhances the potential of human γδ T cells to provide B-cell help. Eur J Immunol (2012) 42:110-9. doi:10.1002/eji.201142017
25. Caccamo N, Todaro M, La Manna MP, Sireci G, Stassi G, Dieli F. IL-21 regulates the differentiation of a human γδ T cell subset equipped with B cell helper activity. PLoS One (2012) 7:e41940. doi:10.1371/journal.pone.0041940
26. Casetti R, Agrati C, Wallace M, Sacchi A, Martini F, Martino A, et al. TGF-β1 and IL-15 Induce FOXP3+ γδ regulatory T cells in the presence of antigen stimulation. J Immunol (2009) 183:3574-7. doi:10.4049/jimmunol.0901334
27. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol (2006) 90:1-50. doi:10.1016/S0065-2776(06)90001-7
28. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 6:383-93. doi:10.1038/nri1842
29. Kunzmann V, Bauer E, Feurle J, Weihinger F, Torny HP, Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of anti plasma cell activity in multiple myeloma. Blood (2000) 86:384-92.
30. Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E, et al. Vγ9Vδ2 T cell response to colon carcinoma cells. J Immunol (2005) 175:5481-8. doi:10.4049/jimmunol.175.8.5481
31. Belmant C, Decise D, Fournie JJ. Phosphoantigens and aminobisphosphonates: new leads targeting γδ T lymphocytes for cancer immunotherapy. Drug Discov Today Ther Strateg (2006) 3:17-23. doi:10.1016/j.ddstr.2006.02.001
32. Liu Z, Guo BL, Gehrs BC, Nan L, Lopez RD. Ex vivo expanded human Vγ9Vδ2 γδ+ T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J Urol (2005) 173:1552-6. doi:10.1097/01.ju.0000154355.45816.0b
33. Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, et al. Phosphostim activated γδ T cells kill autologous metastatic renal cell carcinoma. J Immunol (2005) 174:1338-47. doi:10.4049/jimmunol.174.3.1338
34. Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human Vγ9Vδ2 γδT cells in vitro and in SCID mice in vivo. J Immunol (2004) 173:6767-76. doi:10.4049/jimmunol.173.11.6767
35. D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, et al. Vγ9Vδ2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol (2010) 184:3260-8. doi:10.4049/jimmunol.0903454
36. Harwood HJ Jr, Alvarez IM, Noyes WD, Stacpoole PW. In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma. J Lipid Res (1991) 32:1237-52.
37. Kunzmann V, Bauer E, Wilhelm M. γδ T-cell stimulation by pamidronate. N Engl J Med (1999) 340:737-8. doi:10.1056/NEJM199903043400914
38. Girlanda S, Fortis C, Belloni D, Ferrero E, Ticozzi P, Sciorati C, et al. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells co-stimulates pamidronate-activated γδ lymphocytes. Cancer Res (2005) 65:7502-8. doi:10.1158/0008-5472.CAN-05-0731
39. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, et al. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood (2003) 102:2310-1. doi:10.1182/blood-2003-05-1655
40. Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T, et al. MICA engagement by human Vγ9Vδ2 T cells enhances their antigen dependent effector function. Immunity (2001) 15:83-93. doi:10.1016/S1074-7613(01)00168-6
41. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of Vγ9Vδ2 T cells by NKG2D. J Immunol (2005) 175:2144-51. doi:10.4049/jimmunol.175.4.2144
42. Lanca T, Correia DV, Moita CF, Raquel H, Neves-Costa A, Ferreira C, et al. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to γδ T-cell cytotoxicity. Blood (2010) 115:2407-11. doi:10.1182/blood-2009-08-237123
43. Gomes AQ, Correia DV, Grosso AR, Lança T, Ferreira C, Lacerda JF, et al. Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood γδ T cells. Haematologica (2010) 95:1397-404. doi:10.3324/haematol.2009.020602
44. Dieli F, Troye-Blomberg M, Ivanyi J, Fournie M, Bonneville MA, Peyrat G, et al. Granulysin dependent killing of intracellular and extracellular Mycobacterium tuberculosis by Vγ9Vδ2 T lymphocytes. J Infect Dis (2001) 184:1082-5. doi:10.1086/323600
45. Vermijlen D, Ellis P, Langford C, Klein A, Engel R, Willimann K, et al. Distinct cytokine driven responses of activated blood γδ T cells: insights into unconventional T cell pleiotropy. J Immunol (2007) 178:4304-14. doi:10.4049/jimmunol.178.7.4304
46. Dalton JE, Howell G, Pearson J, Scott P, Carding SR. Fas-Fas ligand interactions are essential for the binding to and killing of activated macrophages by γδ. J Immunol (2004) 173:3660-7. doi:10.4049/jimmunol.173.6.3660
47. Ismaili J, Olislagers V, Poupot R, Fournie JJ, Goldman M. Human γδ T cells induce dendritic cell maturation. Clin Immunol (2002) 103:296-302. doi:10.1006/clim.2002.5218
48. Conti L, Casetti R, Cardone M, Varano B, Martino A, Belardelli F, et al. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated γδ T cells: role of CD86 and inflammatory cytokines. J Immunol (2005) 174:252-60. doi:10.4049/jimmunol.174.1.252
49. Devilder MC, Maillet S, Bouyge-Moreau I, Donnadieu E, Bonneville M, Scotet E. Potentiation of antigen-stimulated Vγ9Vδ2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. J Immunol (2006) 176:1386-93. doi:10.4049/jimmunol.176.3.1386
50. Buccheri S, Guggino G, Caccamo N, Li Donni P, Dieli F. Efficacy and safety of γδ T cell-based tumor immunotherapy: a meta-analysis. J Biol Regul Homeost Agents (2014) 28:81-90.
51. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer (2011) 105:93-103. doi:10.1038/bjc.2011.189
52. Sasada T, Suekane S. Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. Immunotherapy (2011) 3:1235-51. doi:10.2217/imt.11.106
53. Bialasiewicz AA, Ma JX, Richard G. αβ- and γδ TCR+ lymphocyte infiltration in necrotising choroidal melanomas. Br J Ophthalmol (1999) 83:1069-73. doi:10.1136/bjo.83.9.1069
54. Inman BA, Frigola X, Harris KJ, Kuntz SM, Lohse CM, Leibovich BC, et al. Questionable relevance of γδ T lymphocytes in renal cell carcinoma. J Immunol (2008) 180:3578-84. doi:10.4049/jimmunol.180.5.3578
55. Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Wevers E, et al. Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J Immunol (2012) 189:5029-36. doi:10.4049/jimmunol.1201892
56. Cordova A, Toia F, La Mendola C, Orlando V, Meraviglia S, Rinaldi G, et al. Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas. PLoS One (2012) 7:e49878. doi:10.1371/journal.pone.0049878
57. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, et al. γδ T17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity (2014) 40:785-800. doi:10.1016/j.immuni.2014.03.013
58. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. Proc Natl Acad Sci U S A (1999) 96:6879-84. doi:10.1073/pnas.96.12.6879
59. Chen J, Niu H, He W, Ba D. Antitumor activity of expanded human tumor-infiltrating γδ T lymphocytes. Int Arch Allergy Immunol (2001) 125:256-63. doi:10.1159/000053824
60. Choudhary A, Davodeau F, Moreau A, Peyrat MA, Bonneville M, Jotereau F. Selective lysis of autologous tumor cells by recurrent γδ tumor-infiltrating lymphocytes from renal carcinoma. J Immunol (1995) 154:3932-40.
61. Ferrarini M, Heltai S, Pupa SM, Mernard S, Zocchi R. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing γδ+ T-cell receptors. J Natl Cancer Inst (1996) 88:436-41. doi:10.1093/jnci/88.7.436
62. Maeurer MJ, Martin D, Walter W, Liu K, Zitvogel L, Halusczcak K, et al. Human intestinal Vδ1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med (1996) 183:1681-96. doi:10.1084/jem.183.4.1681
63. Kitayama J, Atomi Y, Nagawa H, Kuroda A, Mutoh T, Minami M, et al. Functional analysis of TCR γδ+ T cells in tumour-infiltrating lymphocytes (TIL) of human pancreatic cancer. Clin Exp Immunol (1993) 93:442-7. doi:10.1111/j.1365-2249.1993.tb08198.x
64. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating γδ T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity (2007) 27:334-48. doi:10.1016/j.immuni.2007.05.020
65. Ye J, Ma C, Hsueh EC, Eickhoff CS, Zhang Y, Varvares MA, et al. Tumor-derived γδ regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J Immunol (2013) 190:2403-14. doi:10.4049/jimmunol.1202369
66. Wakita D, Sumida K, Iwakura Y, Nishikawa H, Ohkuri T, Chamoto K, et al. Tumor-infiltrating IL-17-producing γδ T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol (2010) 40:1927-37. doi:10.1002/eji.200940157
67. Ma S, Cheng Q, Cai Y, Gong H, Wu Y, Yu X, et al. IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res (2014) 74:1969-82. doi:10.1158/0008-5472.CAN-13-2534
68. Rei M, Gonçalves-Sousa N, Lança T, Thompson RG, Mensurado S, Balkwill FR, et al. Murine CD27- Vγ6+ γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc Natl Acad Sci U S A (2014) 111:E3562-70. doi:10.1073/pnas.1403424111
69. Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S, et al. STAT3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol (2005) 174:3925-31. doi:10.4049/jimmunol.174.7.3925
70. Ugurel S, Schrama D, Keller G, Schadendorf D, Bröcker EB, Houben R, et al. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother (2008) 57:685-91. doi:10.1007/s00262-007-0407-z
71. Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M, Stassi G. Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol (2013) 23:522-32. doi:10.1016/j.semcancer.2013.08.007
72. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell (2014) 14:342-56. doi:10.1016/j.stem.2014.01.009
73. Atre N, Thomas L, Mistry R, Pathak K, Chiplunkar S. Role of nitric oxide in heat shock protein induced apoptosis of gammadeltaT cells. Int J Cancer (2006) 119:1368-76. doi:10.1002/ijc.21966
74. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P. The polarization of immune cells in the tumour environment by TGFβ. Nat Rev Immunol (2010) 10:554-67. doi:10.1038/nri2808
75. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 331:1612-6. doi:10.1126/science.1198443
76. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 14:1014-22. doi:10.1038/ni.2703
77. Burnette B, Fu YX, Weichselbaum RR. The confluence of radiotherapy and immunotherapy. Front Oncol (2012) 2:143. doi:10.3389/fonc.2012.00143
78. Todaro M, Meraviglia S, Caccamo N, Stassi G, Dieli F. Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells. Oncoimmunology (2013) 2:e25821. doi:10.4161/onci.25821
79. Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, et al. Efficient killing of human colon cancer stem cells by γδ T lymphocytes. J Immunol (2009) 182:7287-96. doi:10.4049/jimmunol.0804288
80. Santolaria T, Robard M, Léger A, Catros V, Bonneville M, Scotet E. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo. J Immunol (2013) 191:1993-2000. doi:10.4049/jimmunol.1300255
81. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, et al. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med (2010) 14:2803-15. doi:10.1111/j.1582-4934.2009.00926.x